FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W98169651> ?p ?o ?g. }

• W98169651 endingPage "114" @default.
• W98169651 startingPage "105" @default.
• W98169651 abstract "Purpose To evaluate the efficacy and safety of gemcitabine and carboplatin in the treatment of previously untreated patients with advanced non-small cell lung cancer (NSCLC). Methods A randomized phase II study was conducted by the Groupe Français de Pneumo-Cancérologie (GFPC) in 15 centers. The patients were randomized in either arm A (GC): gemcitabine 1250 mg/m2 on days 1 and 8 + carboplatin AUC 6 mg/(mL min) on day 1; or in arm B (VP): vinorelbine 30 mg/m2 weekly + cisplatin 80 mg/m2 on day 1. Treatment cycles were repeated every 3 weeks. Results A total of 100 patients were randomized with stage IV or stage III NSCLC with malignant pleural effusion: 51 patients in arm A and 49 patients in arm B. A total of 190 cycles were administered in the GC arm and 172 cycles in the VP arm, with a median of four cycles per patient in each arm. The dose intensity was 84.9% for gemcitabine, 99.8% for carboplatin, 97.7% for cisplatin and 67.7% for vinorelbine. The objective response rates were 19.6% (95% CI, 9.8–33.1) for GC and 29.2% (95% CI, 17.0–44.1) for VP in an ITT analysis. The response duration was 169 days in arm A and 226 days in arm B. The TTP was similar with 140 days (GC) and 148 days (VP), respectively. Overall survival rates were 334 days in the GC combination and 304 days in the VP combination. Overall, the treatment was safe and toxicities observed were different in each arm: neutropenia was the most common toxicity in the VP treatment, whereas thrombocytopenia was more frequent in the GC combination. Anemia was similar in both arms. Non-haematologic toxicity was mild. One toxic death in arm A and three toxic deaths in arm B were observed. Conclusion In terms of response rate, the gemcitabine–carboplatin combination was not efficient enough to allow further phase III study. Survival data are in the same range as the standard arm. This chemotherapy is feasible and may represent an alternative to a standard cisplatin-based regimen, allowing treatment in an outpatient setting. To evaluate the efficacy and safety of gemcitabine and carboplatin in the treatment of previously untreated patients with advanced non-small cell lung cancer (NSCLC). A randomized phase II study was conducted by the Groupe Français de Pneumo-Cancérologie (GFPC) in 15 centers. The patients were randomized in either arm A (GC): gemcitabine 1250 mg/m2 on days 1 and 8 + carboplatin AUC 6 mg/(mL min) on day 1; or in arm B (VP): vinorelbine 30 mg/m2 weekly + cisplatin 80 mg/m2 on day 1. Treatment cycles were repeated every 3 weeks. A total of 100 patients were randomized with stage IV or stage III NSCLC with malignant pleural effusion: 51 patients in arm A and 49 patients in arm B. A total of 190 cycles were administered in the GC arm and 172 cycles in the VP arm, with a median of four cycles per patient in each arm. The dose intensity was 84.9% for gemcitabine, 99.8% for carboplatin, 97.7% for cisplatin and 67.7% for vinorelbine. The objective response rates were 19.6% (95% CI, 9.8–33.1) for GC and 29.2% (95% CI, 17.0–44.1) for VP in an ITT analysis. The response duration was 169 days in arm A and 226 days in arm B. The TTP was similar with 140 days (GC) and 148 days (VP), respectively. Overall survival rates were 334 days in the GC combination and 304 days in the VP combination. Overall, the treatment was safe and toxicities observed were different in each arm: neutropenia was the most common toxicity in the VP treatment, whereas thrombocytopenia was more frequent in the GC combination. Anemia was similar in both arms. Non-haematologic toxicity was mild. One toxic death in arm A and three toxic deaths in arm B were observed. In terms of response rate, the gemcitabine–carboplatin combination was not efficient enough to allow further phase III study. Survival data are in the same range as the standard arm. This chemotherapy is feasible and may represent an alternative to a standard cisplatin-based regimen, allowing treatment in an outpatient setting." @default.
• W98169651 created "2016-06-24" @default.
• W98169651 creator A5004829147 @default.
• W98169651 creator A5023065527 @default.
• W98169651 creator A5023584142 @default.
• W98169651 creator A5023846159 @default.
• W98169651 creator A5033220886 @default.
• W98169651 creator A5039103158 @default.
• W98169651 creator A5040900859 @default.
• W98169651 creator A5043045128 @default.
• W98169651 creator A5047594386 @default.
• W98169651 creator A5063465326 @default.
• W98169651 creator A5072758102 @default.
• W98169651 date "2006-01-01" @default.
• W98169651 modified "2023-09-26" @default.
• W98169651 title "Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer" @default.
• W98169651 cites W1550111394 @default.
• W98169651 cites W1938837918 @default.
• W98169651 cites W1964414545 @default.
• W98169651 cites W1984254136 @default.
• W98169651 cites W1988338874 @default.
• W98169651 cites W1993312546 @default.
• W98169651 cites W2012346354 @default.
• W98169651 cites W2021897895 @default.
• W98169651 cites W2039258586 @default.
• W98169651 cites W2041591117 @default.
• W98169651 cites W2049190121 @default.
• W98169651 cites W2050119069 @default.
• W98169651 cites W2061378950 @default.
• W98169651 cites W2064761286 @default.
• W98169651 cites W2116996913 @default.
• W98169651 cites W2124830463 @default.
• W98169651 cites W2128746268 @default.
• W98169651 cites W2129793485 @default.
• W98169651 cites W2146014573 @default.
• W98169651 cites W2151408213 @default.
• W98169651 cites W2160354293 @default.
• W98169651 cites W2172202839 @default.
• W98169651 cites W2256453366 @default.
• W98169651 cites W2262092684 @default.
• W98169651 cites W4239714259 @default.
• W98169651 doi "https://doi.org/10.1016/j.lungcan.2005.10.004" @default.
• W98169651 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16310886" @default.
• W98169651 hasPublicationYear "2006" @default.
• W98169651 type Work @default.
• W98169651 sameAs 98169651 @default.
• W98169651 citedByCount "19" @default.
• W98169651 countsByYear W981696512012 @default.
• W98169651 countsByYear W981696512013 @default.
• W98169651 countsByYear W981696512014 @default.
• W98169651 countsByYear W981696512015 @default.
• W98169651 countsByYear W981696512017 @default.
• W98169651 countsByYear W981696512020 @default.
• W98169651 crossrefType "journal-article" @default.
• W98169651 hasAuthorship W98169651A5004829147 @default.
• W98169651 hasAuthorship W98169651A5023065527 @default.
• W98169651 hasAuthorship W98169651A5023584142 @default.
• W98169651 hasAuthorship W98169651A5023846159 @default.
• W98169651 hasAuthorship W98169651A5033220886 @default.
• W98169651 hasAuthorship W98169651A5039103158 @default.
• W98169651 hasAuthorship W98169651A5040900859 @default.
• W98169651 hasAuthorship W98169651A5043045128 @default.
• W98169651 hasAuthorship W98169651A5047594386 @default.
• W98169651 hasAuthorship W98169651A5063465326 @default.
• W98169651 hasAuthorship W98169651A5072758102 @default.
• W98169651 hasConcept C126322002 @default.
• W98169651 hasConcept C126894567 @default.
• W98169651 hasConcept C141071460 @default.
• W98169651 hasConcept C168563851 @default.
• W98169651 hasConcept C2776256026 @default.
• W98169651 hasConcept C2776694085 @default.
• W98169651 hasConcept C2778239845 @default.
• W98169651 hasConcept C2779634585 @default.
• W98169651 hasConcept C2780258809 @default.
• W98169651 hasConcept C2780350996 @default.
• W98169651 hasConcept C2781451048 @default.
• W98169651 hasConcept C71924100 @default.
• W98169651 hasConcept C90924648 @default.
• W98169651 hasConceptScore W98169651C126322002 @default.
• W98169651 hasConceptScore W98169651C126894567 @default.
• W98169651 hasConceptScore W98169651C141071460 @default.
• W98169651 hasConceptScore W98169651C168563851 @default.
• W98169651 hasConceptScore W98169651C2776256026 @default.
• W98169651 hasConceptScore W98169651C2776694085 @default.
• W98169651 hasConceptScore W98169651C2778239845 @default.
• W98169651 hasConceptScore W98169651C2779634585 @default.
• W98169651 hasConceptScore W98169651C2780258809 @default.
• W98169651 hasConceptScore W98169651C2780350996 @default.
• W98169651 hasConceptScore W98169651C2781451048 @default.
• W98169651 hasConceptScore W98169651C71924100 @default.
• W98169651 hasConceptScore W98169651C90924648 @default.
• W98169651 hasIssue "1" @default.
• W98169651 hasLocation W981696511 @default.
• W98169651 hasLocation W981696512 @default.
• W98169651 hasOpenAccess W98169651 @default.
• W98169651 hasPrimaryLocation W981696511 @default.
• W98169651 hasRelatedWork W1989384257 @default.
• W98169651 hasRelatedWork W2047550201 @default.

• next